Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
| NCT03575078 | ARQ761 + PARP Inhibitor in Refractory Solid Tumors | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Sep 25, 2019 | clinicaltrials |
| NCT03738111 |
| Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma |
| withdrawn |
| Phase 1 |
| 0 |
| Lee's Pharmaceutical LimitedINDUSTRY |
| 0 |
| Sep 25, 2019 |
| clinicaltrials |
| NCT02449967 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02053545 | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion | withdrawn | Phase 1 / Phase 2 | 0 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)(PARADIGMA) | withdrawn | Phase 1 | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03029871 | Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer(NSCLC) | withdrawn | Phase 1 | 0 | Benjamin Movsas, M.D.OTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03057509 | A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03652233 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jun 20, 2019 | clinicaltrials |
| NCT02182622 | LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | withdrawn | Phase 1 | 0 | Martin GutierrezOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 6, 2019 | clinicaltrials |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02581501 | Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | Stamford HospitalOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT03166254 | Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Apr 12, 2019 | clinicaltrials |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Scripps HealthOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT00968604 | C-VISA BikDD: Liposome in Advanced Pancreatic Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 10, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02868632 | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | NYU Langone HealthOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03437070 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | withdrawn | Phase 1 | 0 | University of MiamiOTHER | 0 | Mar 18, 2019 | clinicaltrials |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Joseph JurcicOTHER | 0 | Mar 8, 2019 | clinicaltrials |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | withdrawn | Phase 1 | 0 | Peking UniversityOTHER | 0 | Mar 6, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | withdrawn | Phase 1 | 0 | Michael ChoiOTHER | 0 | Jan 25, 2019 | clinicaltrials |
| NCT00547443 | Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02657447 | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | withdrawn | Phase 1 | 0 | Nordic NanovectorINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02378922 | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT03591744 | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 4 | Dec 11, 2018 | clinicaltrials |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00005030 | SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 14, 2018 | clinicaltrials |
| NCT03496519 | Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors | withdrawn | Phase 1 | 0 | University of Colorado, DenverOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT02845414 | Study of CD133KDEL Toxin in the Treatment for Solid Tumors | withdrawn | Phase 1 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Sep 27, 2018 | clinicaltrials |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT02939846 | Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2019source: clinicaltrials